Department of Neurology, Brain Research Institute, Niigata University, Niigata, Japan.
Department of Molecular Genetics, Brain Research Institute, Niigata University, Niigata, Japan.
Parkinsonism Relat Disord. 2022 Sep;102:30-35. doi: 10.1016/j.parkreldis.2022.07.007. Epub 2022 Jul 30.
Multiple system atrophy (MSA) is a progressive neurodegenerative disorder. The usefulness of biomarkers in diagnosing MSA has been recently reported, but few studies have investigated the correlations among cerebrospinal fluid (CSF) biomarkers or the relationship between CSF biomarkers and the clinical parameters of patients with MSA. Thus, this was the aim of our study.
We performed cross-sectional study of CSF biomarkers in 50 patients with MSA and 20 control subjects. Ten of the patients with MSA were longitudinally followed for a period of 2 ± 1 years (mean ± standard deviation) as a substudy. We quantified CSF biomarkers including α-synuclein (α-syn), β-amyloid42 (Aβ42), total tau (t-tau) and phosphorylated tau (p-tau), neurofilament light chain (NfL), and neuron-glia2 (NG2), and assessed their relationship with clinical parameters (clinical subtypes, motor symptoms, nonmotor symptoms, and disease progression).
The levels of CSF α-syn, Aβ42, and p-tau were significantly lower, while those of NfL were higher in the patients with MSA than in the control subjects. Importantly, we found the significant elevation of soluble NG2 in the CSF of patients with MSA. CSF NfL showed the optimal diagnostic performance for MSA with levels at baseline significantly associated with longitudinal motor progression. With the exception of t-tau, there were no differences in the levels of CSF biomarkers between the MSA-parkinsonism and MSA-cerebellar subtypes.
Our results suggest CSF levels of NG2 and NfL as possible diagnostic and prognostic biomarkers in MSA. Further study is necessary to validate these findings.
多系统萎缩(MSA)是一种进行性神经退行性疾病。生物标志物在 MSA 诊断中的作用最近已有报道,但很少有研究调查脑脊液(CSF)生物标志物之间的相关性或 CSF 生物标志物与 MSA 患者临床参数之间的关系。因此,这是我们研究的目的。
我们对 50 例 MSA 患者和 20 例对照进行了 CSF 生物标志物的横断面研究。其中 10 例 MSA 患者作为亚组进行了为期 2±1 年的纵向随访。我们定量测定了 CSF 生物标志物,包括α-突触核蛋白(α-syn)、β-淀粉样蛋白 42(Aβ42)、总tau(t-tau)和磷酸化 tau(p-tau)、神经丝轻链(NfL)和神经元-胶质 2(NG2),并评估了它们与临床参数(临床亚型、运动症状、非运动症状和疾病进展)的关系。
与对照组相比,MSA 患者的 CSF α-syn、Aβ42 和 p-tau 水平显著降低,而 NfL 水平显著升高。重要的是,我们发现 MSA 患者 CSF 中可溶性 NG2 显著升高。CSF NfL 对 MSA 具有最佳的诊断性能,基线水平与纵向运动进展显著相关。除 t-tau 外,MSA-帕金森病和 MSA-小脑亚型患者的 CSF 生物标志物水平无差异。
我们的研究结果表明 CSF 中 NG2 和 NfL 水平可能是 MSA 的诊断和预后生物标志物。需要进一步的研究来验证这些发现。